308 related articles for article (PubMed ID: 31068200)
1. TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers.
Del-Aguila JL; Benitez BA; Li Z; Dube U; Mihindukulasuriya KA; Budde JP; Farias FHG; Fernández MV; Ibanez L; Jiang S; Perrin RJ; Cairns NJ; Morris JC; Harari O; Cruchaga C
Mol Neurodegener; 2019 May; 14(1):18. PubMed ID: 31068200
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status.
Piccio L; Deming Y; Del-Águila JL; Ghezzi L; Holtzman DM; Fagan AM; Fenoglio C; Galimberti D; Borroni B; Cruchaga C
Acta Neuropathol; 2016 Jun; 131(6):925-33. PubMed ID: 26754641
[TBL] [Abstract][Full Text] [Related]
3. Expression and processing analyses of wild type and p.R47H TREM2 variant in Alzheimer's disease brains.
Ma L; Allen M; Sakae N; Ertekin-Taner N; Graff-Radford NR; Dickson DW; Younkin SG; Sevlever D
Mol Neurodegener; 2016 Nov; 11(1):72. PubMed ID: 27887626
[TBL] [Abstract][Full Text] [Related]
4. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.
Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Schlepckow K; Araque Caballero MÁ; Franzmeier N; Capell A; Fellerer K; Nuscher B; Eren E; Levin J; Deming Y; Piccio L; Karch CM; Cruchaga C; Shaw LM; Trojanowski JQ; Weiner M; Ewers M; Haass C;
Mol Neurodegener; 2019 Jan; 14(1):1. PubMed ID: 30630532
[TBL] [Abstract][Full Text] [Related]
5. Variants in the MS4A cluster interact with soluble TREM2 expression on biomarkers of neuropathology.
Winfree RL; Nolan E; Dumitrescu L; Blennow K; Zetterberg H; Gifford KA; Pechman KR; Seto M; Petyuk VA; Wang Y; Schneider J; Bennett DA; Jefferson AL; Hohman TJ;
Mol Neurodegener; 2024 May; 19(1):41. PubMed ID: 38760857
[TBL] [Abstract][Full Text] [Related]
6. Alternative Splicing Regulation of Low-Frequency Genetic Variants in Exon 2 of
Han S; Na Y; Koh I; Nho K; Lee Y
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576031
[No Abstract] [Full Text] [Related]
7. Coding variants in TREM2 increase risk for Alzheimer's disease.
Jin SC; Benitez BA; Karch CM; Cooper B; Skorupa T; Carrell D; Norton JB; Hsu S; Harari O; Cai Y; Bertelsen S; Goate AM; Cruchaga C
Hum Mol Genet; 2014 Nov; 23(21):5838-46. PubMed ID: 24899047
[TBL] [Abstract][Full Text] [Related]
8. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
Heslegrave A; Heywood W; Paterson R; Magdalinou N; Svensson J; Johansson P; Öhrfelt A; Blennow K; Hardy J; Schott J; Mills K; Zetterberg H
Mol Neurodegener; 2016 Jan; 11():3. PubMed ID: 26754172
[TBL] [Abstract][Full Text] [Related]
9. Frontobasal gray matter loss is associated with the TREM2 p.R47H variant.
Luis EO; Ortega-Cubero S; Lamet I; Razquin C; Cruchaga C; Benitez BA; Lorenzo E; Irigoyen J; ; Pastor MA; Pastor P
Neurobiol Aging; 2014 Dec; 35(12):2681-2690. PubMed ID: 25027412
[TBL] [Abstract][Full Text] [Related]
10. TREM2 splice isoforms generate soluble TREM2 species that disrupt long-term potentiation.
Moutinho M; Coronel I; Tsai AP; Di Prisco GV; Pennington T; Atwood BK; Puntambekar SS; Smith DC; Martinez P; Han S; Lee Y; Lasagna-Reeves CA; Lamb BT; Bissel SJ; Nho K; Landreth GE
Genome Med; 2023 Feb; 15(1):11. PubMed ID: 36805764
[TBL] [Abstract][Full Text] [Related]
11. The
Deming Y; Filipello F; Cignarella F; Cantoni C; Hsu S; Mikesell R; Li Z; Del-Aguila JL; Dube U; Farias FG; Bradley J; Budde J; Ibanez L; Fernandez MV; Blennow K; Zetterberg H; Heslegrave A; Johansson PM; Svensson J; Nellgård B; Lleo A; Alcolea D; Clarimon J; Rami L; Molinuevo JL; Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Ewers M; Harari O; Haass C; Brett TJ; Benitez BA; Karch CM; Piccio L; Cruchaga C
Sci Transl Med; 2019 Aug; 11(505):. PubMed ID: 31413141
[TBL] [Abstract][Full Text] [Related]
12. Soluble TREM2 inhibits secondary nucleation of Aβ fibrillization and enhances cellular uptake of fibrillar Aβ.
Belsare KD; Wu H; Mondal D; Bond A; Castillo E; Jin J; Jo H; Roush AE; Pilla KB; Sali A; Condello C; DeGrado WF
Proc Natl Acad Sci U S A; 2022 Feb; 119(5):. PubMed ID: 35082148
[TBL] [Abstract][Full Text] [Related]
13. R47H Variant of TREM2 Associated With Alzheimer Disease in a Large Late-Onset Family: Clinical, Genetic, and Neuropathological Study.
Korvatska O; Leverenz JB; Jayadev S; McMillan P; Kurtz I; Guo X; Rumbaugh M; Matsushita M; Girirajan S; Dorschner MO; Kiianitsa K; Yu CE; Brkanac Z; Garden GA; Raskind WH; Bird TD
JAMA Neurol; 2015 Aug; 72(8):920-7. PubMed ID: 26076170
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.
Woollacott IOC; Nicholas JM; Heslegrave A; Heller C; Foiani MS; Dick KM; Russell LL; Paterson RW; Keshavan A; Fox NC; Warren JD; Schott JM; Zetterberg H; Rohrer JD
Alzheimers Res Ther; 2018 Aug; 10(1):79. PubMed ID: 30111356
[TBL] [Abstract][Full Text] [Related]
15. Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury.
Suárez-Calvet M; Araque Caballero MÁ; Kleinberger G; Bateman RJ; Fagan AM; Morris JC; Levin J; Danek A; Ewers M; Haass C;
Sci Transl Med; 2016 Dec; 8(369):369ra178. PubMed ID: 27974666
[TBL] [Abstract][Full Text] [Related]
16. The Trem2 R47H Alzheimer's risk variant impairs splicing and reduces Trem2 mRNA and protein in mice but not in humans.
Xiang X; Piers TM; Wefers B; Zhu K; Mallach A; Brunner B; Kleinberger G; Song W; Colonna M; Herms J; Wurst W; Pocock JM; Haass C
Mol Neurodegener; 2018 Sep; 13(1):49. PubMed ID: 30185230
[TBL] [Abstract][Full Text] [Related]
17. Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers.
Ashton NJ; Suárez-Calvet M; Heslegrave A; Hye A; Razquin C; Pastor P; Sanchez-Valle R; Molinuevo JL; Visser PJ; Blennow K; Hodges AK; Zetterberg H
Alzheimers Res Ther; 2019 Nov; 11(1):94. PubMed ID: 31779670
[TBL] [Abstract][Full Text] [Related]
18. Differential splicing of neuronal genes in a Trem2*R47H mouse model mimics alterations associated with Alzheimer's disease.
Pandey RS; Kotredes KP; Sasner M; Howell GR; Carter GW
BMC Genomics; 2023 Apr; 24(1):172. PubMed ID: 37016304
[TBL] [Abstract][Full Text] [Related]
19. Investigation of pathology, expression and proteomic profiles in human TREM2 variant postmortem brains with and without Alzheimer's disease.
Toomey CE; Heywood W; Benson BC; Packham G; Mills K; Lashley T
Brain Pathol; 2020 Jul; 30(4):794-810. PubMed ID: 32267026
[TBL] [Abstract][Full Text] [Related]
20. Transcriptomics and mechanistic elucidation of Alzheimer's disease risk genes in the brain and in vitro models.
Martiskainen H; Viswanathan J; Nykänen NP; Kurki M; Helisalmi S; Natunen T; Sarajärvi T; Kurkinen KM; Pursiheimo JP; Rauramaa T; Alafuzoff I; Jääskeläinen JE; Leinonen V; Soininen H; Haapasalo A; Huttunen HJ; Hiltunen M
Neurobiol Aging; 2015 Feb; 36(2):1221.e15-28. PubMed ID: 25281018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
